CTI BioPharma Corp. | Mutual Funds
Mutual Funds that own CTI BioPharma Corp.
FTIF SICAV - Franklin Biotechnology Discovery Fund
2,133,300
3.68%
0
0.17%
06/30/2018
Vanguard Total Stock Market Index Fund
1,390,899
2.4%
0
0%
07/31/2018
Franklin Biotechnology Discovery Fund
1,339,000
2.31%
1,339,000
0.17%
03/31/2018
Fidelity Select Biotechnology Portfolio
1,073,300
1.85%
0
0.02%
07/31/2018
iShares Russell 2000 ETF
1,069,243
1.84%
-570
0%
09/06/2018
Vanguard Extended Market Index Fund
669,823
1.15%
9,000
0%
07/31/2018
iShares Russell 2000 Growth ETF
501,352
0.87%
0
0.01%
09/06/2018
Fidelity Advisor Biotechnology Fund
257,031
0.44%
-69,669
0.02%
07/31/2018
Fidelity Spartan Extended Market Index Fund
236,561
0.41%
0
0%
07/31/2018
Driehaus Micro Cap Growth Fund
226,045
0.39%
8,517
0.09%
06/30/2018
| Address |
3101 Western Avenue
Seattle Washington 98121
United States
|
|
Employees
|
- |
| Website |
http://www.ctibiopharma.com |
| Updated |
07/08/2019 |
| CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. |
